Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy

溶瘤病毒 水泡性口炎病毒 牛痘 病毒 癌症研究 病毒学 抗原 T细胞 免疫疗法 生物 免疫学 免疫系统 生物化学 基因 重组DNA
作者
Zaid Taha,Mathieu J.F. Crupi,Nouf Alluqmani,Duncan S. MacKenzie,Sydney Vallati,Jack T. Whelan,Faiha Fareez,Akram Alwithenani,Julia Petryk,Andrew X. Chen,Marcus M. Spinelli,K. W. Ng,Judy Sobh,Christiano Tanese de Souza,Priya Rose Bharadwa,Timothy Kit Hin Lee,Dylan Anthony Thomas,Ben Zhen Huang,Omar Kassas,Joanna Poutou,Victoria H. Gilchrist,Stephen Boulton,Max Thomson,Ricardo Marius,Mohsen Hooshyar,Scott McComb,Rozanne Arulanandam,Carolina S. Ilkow,John C. Bell,Jean‐Simon Diallo
出处
期刊:Nature Communications [Springer Nature]
卷期号:15 (1)
标识
DOI:10.1038/s41467-024-51498-0
摘要

Targeted antineoplastic immunotherapies have achieved remarkable clinical outcomes. However, resistance to these therapies due to target absence or antigen shedding limits their efficacy and excludes tumours from candidacy. To address this limitation, here we engineer an oncolytic rhabdovirus, vesicular stomatitis virus (VSVΔ51), to express a truncated targeted antigen, which allows for HER2-targeting with trastuzumab. The truncated HER2 (HER2T) lacks signaling capabilities and is efficiently expressed on infected cell surfaces. VSVΔ51-mediated HER2T expression simulates HER2-positive status in tumours, enabling effective treatment with the antibody-drug conjugate trastuzumab emtansine in vitro, ex vivo, and in vivo. Additionally, we combine VSVΔ51-HER2T with an oncolytic vaccinia virus expressing a HER2-targeted T-cell engager. This dual-virus therapeutic strategy demonstrates potent curative efficacy in vivo in female mice using CD3+ infiltrate for anti-tumour immunity. Our findings showcase the ability to tailor the tumour microenvironment using oncolytic viruses, thereby enhancing compatibility with "off-the-shelf" targeted therapies. Oncolytic viruses (OVs) represent a treatment option for patients with cancer. Here the authors propose a tumour-agnostic dual-virus strategy for cancer therapy by generating a vesicular stomatitis virus encoding a truncated version of HER2, combined with a vaccinia virus as a delivery platform for a HER2-targeted T-cell engager.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
初夏完成签到,获得积分10
刚刚
1秒前
脑洞疼应助钟博士采纳,获得10
1秒前
东云完成签到,获得积分10
2秒前
静心404完成签到,获得积分10
2秒前
4秒前
GakkiSmile完成签到,获得积分10
4秒前
love yourself完成签到 ,获得积分10
4秒前
CodeCraft应助科研通管家采纳,获得20
5秒前
科研通AI2S应助科研通管家采纳,获得10
5秒前
Devil驳回了田様应助
5秒前
5秒前
李爱国应助科研通管家采纳,获得10
5秒前
酷波er应助科研通管家采纳,获得10
5秒前
天天快乐应助科研通管家采纳,获得10
5秒前
隐形曼青应助科研通管家采纳,获得10
5秒前
桐桐应助科研通管家采纳,获得10
5秒前
丘比特应助科研通管家采纳,获得10
5秒前
搜集达人应助科研通管家采纳,获得10
6秒前
科研通AI2S应助科研通管家采纳,获得10
6秒前
不配.应助科研通管家采纳,获得20
6秒前
深情安青应助科研通管家采纳,获得10
6秒前
烟花应助科研通管家采纳,获得10
6秒前
天天快乐应助科研通管家采纳,获得10
6秒前
共享精神应助科研通管家采纳,获得10
6秒前
云汐儿应助科研通管家采纳,获得30
6秒前
科研通AI2S应助科研通管家采纳,获得10
6秒前
研友_VZG7GZ应助科研通管家采纳,获得10
6秒前
6秒前
天天快乐应助科研通管家采纳,获得10
6秒前
烂漫念文应助科研通管家采纳,获得10
6秒前
7秒前
7秒前
Jstar发布了新的文献求助20
7秒前
在水一方应助淡淡菠萝采纳,获得10
11秒前
12秒前
qaq发布了新的文献求助10
12秒前
12秒前
向日葵应助IAMXC采纳,获得10
13秒前
13秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3140698
求助须知:如何正确求助?哪些是违规求助? 2791571
关于积分的说明 7799545
捐赠科研通 2447907
什么是DOI,文献DOI怎么找? 1302182
科研通“疑难数据库(出版商)”最低求助积分说明 626459
版权声明 601194